Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas

APMIS

Volumn 116, Issue 5, 2008, Pages 400-409

  Høgdall, Estrid V S ^a   Christensen, Lise ^b   Høgdall, Claus K ^b   Frederiksen, Kirsten ^a   Gayther, Simon ^c   Blaakaer, Jan ^d   Jacobs, Ian J ^c   Kjaer, Susanne K ^a,b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Epithelial ovarian cancer; Immunohistochemistry; p53; Prognosis; Tissue array

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; DENMARK; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVARY TUMOR; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; CARCINOMA; DENMARK; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43049151092     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00917.x     Document Type: Article

References (41)

1. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Canc Res 2004 10 : 3291 300.
2. Kjaer SK, Storm HH. Female genital organs. Survival of Danish Cancer patients 1943-87. APMIS 1993 Suppl 107 21.
3. Rapkiewicz AV, Espina V, Petricoin EF, Liotta LA. Biomarkers of ovarian tumours. Eur J Cancer 2004 40 : 2604 12.
4. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995 45 : 88 101.
5. Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998 77 : 777 81.
6. Weinberg RA. How cancer arises. Sci Am 1996 275 : 32 40.
7. Marjoniemi VM. Immunohistochemistry in gynaecological pathology: a review. Pathology 2004 36 : 109 19.
8. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004 36 : 295 300.
9. Nocito A, Kononen J, Kallioniemi OP, Sauter G. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001 94 : 1 5.
10. Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000 16 : 567 76.
11. DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet 2000 89 : 93 102.
12. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986 6 : 1379 85.
13. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000 89 : 2006 17.
14. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999 18 : 29 41.
15. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997 80 : 892 8.
16. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996 56 : 2178 84.
17. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Canc Res 2001 7 : 2984 97.
18. Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 1998 105 : 3814 25.
19. Malamou-Mitsu V, Crikoni O, Timotheadou E, Aravantinos G, Vrettou E, Agnantis N, et al. Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res 2007 27 : 1157 65.
20. de Graeff P, Hall J, Crijns A, de Bock G, Paul J, Oien K, et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 2006 95 : 627 33.
21. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994 266 : 1821 8.
22. Finlay C, Hinds P, Tan TH, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 comples with an altered half-life. Mol Cell Biol 1988 8 : 531 9.
23. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003 98 : 66 73.
24. Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, et al. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study. Cancer 2003 9 : 2387 95.
25. Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, et al. Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006 15 : 798 803.
26. Engellau J. Prognostic factors in soft tissue sarcoma. Tissue microarray for immunostaining, the importance of whole-tumor sections and time-dependence. Acta Orthop Scand 2004 Suppl 75 2.
27. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972 34 : 187 220.
28. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000 156 : 409 17.
29. Lee H, Park G, Jung JH, Ahn WS, Lee JM, Kim BK, et al. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer 2005 15 : 453 61.
30. Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004 14 : 1086 96.
31. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003 97 : 389 404.
32. Dogan E, Saygili U, Tuna B, Gol M, Gürel D, Acar B, et al. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 2005 97 : 46 52.
33. Plisiecka-Halasa J, Karpinska G, Szymanska T, Ziólkowska I, Madry R, Timorek A, et al. P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 2003 14 : 1078 85.
34. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2002 19 : 301 6.
35. Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004 10 : 538 45.
36. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003 91 : 504 12.
37. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004 10 : 5168 77.
38. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000 77 : 278 82.
39. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001 194 : 68 75.
40. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991 51 : 2979 84.
41. Høgdall EVS, Kjaer SK, Blaakaer J, Christensen L, Glud E, Vuust J, et al. P53 mutations in tissue from Danish ovarian cancer patients. From the Danish "MALOVA" ovarian cancer study. Gynecol Oncol 2006 100 : 76 82.